199339-71-4

Upstream product

• 817586-34-8 2-hydroxy-2-(4-hydroxy-1-benzothiophen-7-yl)acetic acid 
• 3610-02-4 4-hydroxybenzothiophene 
• 817586-35-9 tributylammonium hydroxy-(4-hydroxy-benzo[b]thiophen-7-yl)-acetate 

Downstream Products

• 668479-00-3 [rac]-4-[2-(5-methyl-2-p-tolyl-thiazol-4-yl)-ethoxy]-benzo[b]thiophene-7-carbaldehyde 
• 475480-80-9 [rac]-2-Isopropoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid 
• 668479-01-4 [rac]-2-ethoxy-3-hydroxy-3-{4-[2-(5-methyl-2-p-tolyl-thiazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid ethyl ester 
• 1189748-84-2 C₂₇H₂₁NO₃S 
• 1189748-76-2 C₂₂H₁₆F₃NO₃S 
• 475480-88-7 4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophene-7-carbaldehyde 
• 1160811-11-9 C₂₃H₂₁NO₃S 
• 1160811-09-5 C₂₂H₁₉NO₄S 
• 1160811-12-0 C₂₃H₂₁NO₅S 
• 1189748-77-3 C₂₄H₂₃NO₃S 

Relevant academic research and scientific papers

Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.

GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows: wherein Y, R1, G, and Q are defined herein; and wherein R11, R21, R41, RB1 and G1, are defined herein.

Process for the production of chiral propionic acid derivatives

The present invention is concerned with a novel process for the preparation of compounds of formula I comprising catalytic asymmetric hydrogenation of a compound of formula (II) in the presence of a catalyst comprising ruthenium and a chiral diphosphine ligand or comprising rhodium and a chiral diphosphine ligand, wherein R1, R2, R3 and R4 are as defined in the specification and claims. The compounds of formula I and the corresponding salts and/or esters are pharmaceutically active substances.

Novel process for the preparation of the insulin sensitizer

A novel process for the preparation of compounds of formula I and optionally converting a compound of formula I into a pharmaceutically acceptable salt is disclosed. The compounds of formula I and the corresponding salts, e.g. the sodium salts, are pharma